tirzepatide suicidal ideation FDA clears GLP-1 weight loss drugs of risk | Hesham Sherif posted on the topic The U.S. health regulator asked

Patients with inflammatory bowel disease considering semaglutide therapy should engage in comprehensive discussions with their healthcare team, ideally involving both their gastroenterologist and the physician prescribing the medication

10.1016/j.diabres.2021.109118 32 PapamargaritisD.Al-NajimW.LimJ.CraneJ.BodicoatD

In a 48-week clinical trial, higher doses consistently led to greater average weight loss: Weight loss by dose (48-week clinical trial) In this trial, at the highest dose (12 mg), people lost an average 24% of their starting weight on average

Start by naming the top issue you want to fix first, then add one tool at a time so you can track irritation and progress without guessing

How GLP-1 Patches Claim to Work GLP-1 patches are marketed as non-invasive, needle-free alternatives to prescription weight loss medications

Lancet (2021) 398:26276